Regorafenib Is Another Potentially Senotherapeutic Tyrosine Kinase Inhibitor

Dasatinib, a tyrosine kinase inhibitor, was one of the first drugs shown to selectively destroy senescent cells and thereby reverse aspects of aging, particularly when used in combination with the plant flavonoid quercetin. Strangely, little attention was given to the question of whether other tyrosine kinase inhibitors can target senescent cells until recently. A number of these compounds have in the past undergone clinical trials, or even been approved for use by regulators, for the treatment of conditions that researchers now suspect to be connected with cellular senescence to a significant degree. Nintedanib, for example, in the context of pulmonary fibrosis, or masitinib in the context of Alzheimer's disease. In today's open access paper, researchers report on another tyrosine kinase inhibitor that may act to reduce the age-related burden of cellular senescence. It is, as one might expect, an approved cancer drug. The dasatinib and quercetin combination remains one of the more effective senolytic therapies in terms of reducing the burden of senescent cells in animal studies. There is no particular reason as to why dasatinib should be the best in its class, however. It is possible that other tyrosine kinase inhibitors are better, either overall, or for specific use cases. Certainly, by analogy, the class of bcl-2 family inhibitors (including navitoclax, one of the other early senolytic drugs) that selectively destroy senescent cells vary widely in effectiveness. ...
Source: Fight Aging! - Category: Research Authors: Tags: Medicine, Biotech, Research Source Type: blogs